The OncoAlly™ Solid Tumor Analysis

OncoAlly Solid Tumor Analysis

OncoAlly™ Solid Tumor Analysis brings clarity and direction to the complexity of treating and managing solid tumors. Using a combination of whole genome sequencing (WGS), exome sequencing, and targeted RNA analysis, we provide comprehensive tumor profiling analysis and treatment optimization based on biomarkers association in 482 cancer related genes. Additionally, we provide pharmacogenomics of 9 genes related to cancer therapy.

With this suite of genomic tools, we compare the tumor and normal tissue to analyze genomic sequence variants. Using these state of the art technologies, we analyze the genome of both the tumor and normal tissue, to detect sequence variants, deletions/insertions, structural variants, copy number alterations, rearrangements, MSI / MMR, TMB, HPV detection, and LOH. 

The comprehensive molecular profile is then analyzed by ClaudIA for Genomics™, our proprietary data management platform, to provide concise molecular results for optimizing therapies.

Molecular Tumor Data:

  • Genomic profiling of driver mutations
  • Prognosis (PFS)
  • Biomarkers of resistance
  • Diagnostic variants (if applicable)
  • Hereditary predisposition (if applicable)
  • HPV status
  • Germline variant detection (available only when receiving a normal tissue comparator)

Optimized Therapeutic Guidance:

  • FDA-approved drugs with biomarkers
  • Investigational therapies based on patient health information and molecular profile
  • NCCN guidelines 
  • Cancer pharmacogenomics 
  • TMB, MMR deficiency for immuno-oncology
  • PD-L1 status 

Turnaround Time

14 days from specimen receipt

Targeted Cancer types

All solid malignancies

Included Genes

Sample types

Tumor tissue: FFPE 

Normal tissue: Blood / FFPE

Sample typewhat to send us
FFPE Samples*10-15 unstained slides (positively charged and unbaked), 5-10 micron thick + 1 terminal H&E (preferred) OR
Tissue Block + 1 H&E OR
Scroll, 20-50 micron thick + 1 H&E
>=30% tumor optimal; 20% tumor minimum
Tissue size: 25mm-2 optimal, minimum 5mm-2 (biopsy)
Normal tissue Blood: Streck tube (tiger top), 10 mL (preferred) OR
Blood: EDTA (purple top), 4mL

FFPE Samples 
10-15 unstained slides (positively charged and unbaked), 5-10 micron thick + 1 terminal H&E (preferred) OR
Tissue Block + 1 H&E OR
Scroll, 20-50 micron thick + 1 H&E
≥30% tumor optimal; 20% tumor minimum
Tissue size: 25mm-2 optimal, minimum 5mm-2 (biopsy)
*For PD-L1: Five additional unstained slides (positively charged and unbaked) are needed

More Information

Our resource center has helpful information about forms, billing, FAQs, and more.

View resources